The Role of EGFR-TK Inhibition in Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|28|12|619-620

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.12, 2005-12, pp. : 619-620

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

The Role of Irinotecan in Non-Small Cell and Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 25-27

Karger

Access to resources Recommend Favorite

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer

By von Eyben Finn  

Critical Reviews in Clinical Laboratory Sciences, Vol. 43, Iss. 4, 2006-08 ,pp. : 291-323

Informa Healthcare

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite